© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Glaukos Corporation (GKOS) stock surged +0.12%, trading at $112.77 on NYSE, up from the previous close of $112.64. The stock opened at $109.76, fluctuating between $108.72 and $113.90 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 02, 2026 | 109.79 | 113.90 | 108.72 | 112.77 | 591.43K |
| Apr 01, 2026 | 108.69 | 113.66 | 107.68 | 112.64 | 1M |
| Mar 31, 2026 | 106.75 | 108.90 | 104.78 | 107.66 | 627.56K |
| Mar 30, 2026 | 103.49 | 105.47 | 102.12 | 105.01 | 607.04K |
| Mar 27, 2026 | 106.74 | 106.74 | 102.12 | 103.18 | 621.27K |
| Mar 25, 2026 | 106.46 | 109.67 | 105.40 | 109.60 | 706.02K |
| Mar 24, 2026 | 105.24 | 107.17 | 103.69 | 105.23 | 781.87K |
| Mar 23, 2026 | 104.13 | 107.84 | 102.24 | 106.84 | 1.09M |
| Mar 20, 2026 | 104.52 | 105.36 | 100.15 | 100.99 | 1.14M |
| Mar 19, 2026 | 102.99 | 104.55 | 100.46 | 102.09 | 599.54K |
| Mar 18, 2026 | 101.70 | 104.64 | 101.29 | 103.22 | 562.18K |
| Mar 17, 2026 | 99.15 | 103.07 | 98.92 | 102.93 | 498.99K |
| Mar 16, 2026 | 97.99 | 99.54 | 96.47 | 98.94 | 476.88K |
| Mar 13, 2026 | 98.43 | 100.73 | 95.98 | 97.02 | 561.03K |
| Mar 12, 2026 | 100.75 | 101.91 | 97.14 | 97.79 | 866.66K |
| Mar 11, 2026 | 102.78 | 104.14 | 100.47 | 102.86 | 508.16K |
| Mar 10, 2026 | 105.81 | 106.78 | 102.30 | 103.15 | 874.64K |
| Mar 09, 2026 | 105.83 | 106.22 | 99.84 | 105.78 | 952.91K |
| Mar 06, 2026 | 110.00 | 110.02 | 106.50 | 107.73 | 622.28K |
| Mar 03, 2026 | 118.52 | 118.52 | 112.66 | 117.75 | 588.98K |
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
| Employees | 995 |
| Beta | 0.78 |
| Sales or Revenue | $314.71M |
| 5Y Sales Change% | 0.255% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |